Boosting productivity and performance in drug discovery with SEQUOIA - Semantic Query of Information Assets

Projektinformationen

SEQUOIA-DD

ID Finanzhilfevereinbarung: 736397

DOI 10.3030/736397

Abgeschlossenes Projekt

EK-Unterschriftsdatum 25 Juli 2016

Startdatum 1 September 2016

Enddatum 28 Februar 2017

Finanziert unter

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

SYNAPSE INFORMATION LIMITED
United Kingdom

Ziel

Synapse Information (UK) have developed a novel semantic web technology, SEQUOIA – Semantic Query of Information Assets – allowing users to rapidly question > 100 disparate data assets in a code-free spreadsheet environment. Having proved the core platform functionality within the financial sector, Synapse now seek to apply SEQUOIA to the field of drug discovery R&D.

New drugs are required urgently to treat cancers & other rare/neurological diseases. However, costs and timescales of drug development are huge due to high failure rates. A principle barrier is the lack of real time comparison of disparate datasets, which can identify causal correlations behind reactions throughout the R&D process. Building on the prototype kernel solution, SEQUOIA targets the many high performance silos of public online drug R&D data, enabling all researchers to semantically probe these ontologies against internal R&D. Synapse therefore aim to catalyse a strategic 10 - 100× productivity gain during the discovery phase to disrupt the €5.5 billion/yr drug discovery software market.

The overall project aims to: fulfil the further technical developments required to transfer SEQUOIA into priority sectors within drug R&D; initiate the technical and commercial partnerships with key stakeholders in the pharmaceutical industry; validate performance through extended field trials; establish regulatory compliance; deliver compatibility with key user data environments; and optimise a developed product.

The proposed Phase 1 feasibility study seeks to address these requirements through: delivery of an elaborated business plan; prioritised EU market entry strategy; analysis of market-held data assets, technical development roadmap; engagement of key stakeholders in the pharmaceutical industry; supply chain initiation; development of IP strategy and value model; as well as regulatory and legal roadmaps for the final phase of developments and exploitation.

Wissenschaftliches Gebiet

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• natural sciences › computer and information sciences › knowledge engineering › ontology
• natural sciences › computer and information sciences › software
• social sciences › economics and business › economics › production economics › productivity
• natural sciences › computer and information sciences › internet › semantic web

Programm/Programme

• H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) Main Programme
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Thema/Themen

• SMEInst-01-2016-2017 - Open Disruptive Innovation Scheme

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2016-2017

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

SYNAPSE INFORMATION LIMITED

• Netto-EU-Beitrag: € 50 000,00
• Adresse: 33 LUDGATE HILL ; B3 1EH BIRMINGHAM ; Vereinigtes Königreich
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  West Midlands (England) › West Midlands › Birmingham
• Region: West Midlands (England) › West Midlands › Birmingham
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00